By Connor Hart
Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company.
SpringWorks stock rose 8.7%, to $44.80, in afternoon trading Thursday. Shares are up 2.3% in the past year.
Both companies have agreed on a price close to $47 a share, according to the report, which cited people familiar with the matter. A deal could be completed as soon as Monday, assuming the talks don't hit any more last-minute snags.
German life-sciences and chemicals company Merck in February said it was in advanced talks to buy SpringWorks, after signaling last year that it was on the lookout for deals.
SpringWorks in late 2023 launched its first drug, Ogsiveo, a therapy for desmoid tumors--a rare type of tumor that occurs in connective tissue--in adults. The business had a market value of a little over $3 billion as of Thursday.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 24, 2025 15:17 ET (19:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。